{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:33:29Z","timestamp":1763987609315},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.bjid.2013.11.005","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T10:45:37Z","timestamp":1391769937000},"page":"187-195","source":"Crossref","is-referenced-by-count":20,"title":["Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011)"],"prefix":"10.1016","volume":"18","author":[{"given":"Robert K.","family":"Flamm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2013.11.005_bib0005","unstructured":"Teflaro\u00ae Package Insert 2012. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/200327s009lbl.pdf [accessed August 2013]."},{"key":"10.1016\/j.bjid.2013.11.005_bib0010","unstructured":"European Medicines Assessment Report for Zinforo (ceftaroline fosamil) Procedure No. EMEA\/H\/C\/002252."},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0015","first-page":"iii45","article-title":"Review of ceftaroline fosamil microbiology: integrated FOCUS studies","volume":"66","author":"Critchley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2013.11.005_bib0020","doi-asserted-by":"crossref","first-page":"iii53","DOI":"10.1093\/jac\/dkr099","article-title":"Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia","volume":"66","author":"Rank","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.bjid.2013.11.005_bib0025","first-page":"iv41","article-title":"CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2013.11.005_bib0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.bjid.2013.11.005_bib0035","first-page":"iv9","article-title":"Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity","volume":"65","author":"Biek","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0040","first-page":"iii11","article-title":"Ceftaroline fosamil: a new broad-spectrum cephalosporin","volume":"66","author":"Laudano","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0045","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2013.11.005_bib0050","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0055","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0060","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1093\/cid\/cis561","article-title":"AWARE ceftaroline surveillance program (2008\u20132010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States","volume":"55","author":"Pfaller","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.bjid.2013.11.005_bib0065","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients: AWARE ceftaroline surveillance program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2013.11.005_bib0070","series-title":"M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition","author":"Clinical Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.bjid.2013.11.005_bib0075","series-title":"M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement","author":"Clinical Laboratory Standards Institute","year":"2013"},{"key":"10.1016\/j.bjid.2013.11.005_bib0080","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0","author":"EUCAST","year":"2013"},{"key":"10.1016\/j.bjid.2013.11.005_bib0085","unstructured":"Tygacil Package Insert. 2011. Wyeth Pharmaceuticals. Available at: www.tygacil.com [accessed January 2013]."},{"key":"10.1016\/j.bjid.2013.11.005_bib0090","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2013.11.005_bib0095","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijantimicag.2012.12.013","article-title":"Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010)","volume":"41","author":"Farrell","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2013.11.005_bib0100","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","article-title":"Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia","volume":"73","author":"Frampton","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bjid.2013.11.005_bib0105","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1128\/AAC.00817-12","article-title":"Activity of ceftaroline\u2013avibactam tested against gram-negative organism populations, including strains expressing one or more beta-lactamases and methicillin-resistant Staphylococcus aureus carrying various SCCmec types","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2013.11.005_bib0110","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/j.ijid.2009.08.018","article-title":"Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America","volume":"14","author":"Rodriguez-Noriega","year":"2010","journal-title":"Int J Infect Dis"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867014000191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867014000191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T16:26:12Z","timestamp":1538843172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867014000191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1413867014000191"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2013.11.005","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}